{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable for n\\<2.","groupId":"OG000","value":"NA"},{"comment":"Not estimable for n\\<2.","groupId":"OG001","lowerLimit":"4.6","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"13.8","upperLimit":"34.9","value":"24.3"},{"groupId":"OG003","lowerLimit":"2.5","upperLimit":"8.8","value":"5.7"},{"groupId":"OG004","lowerLimit":"3.8","upperLimit":"7.3","value":"6.0"},{"groupId":"OG005","lowerLimit":"3.7","upperLimit":"10.1","value":"6.5"},{"comment":"Not estimable.","groupId":"OG006","lowerLimit":"3.7","upperLimit":"NA","value":"8.5"}]}],"title":"RECIST v1.1"},{"categories":[{"measurements":[{"comment":"Not estimable for n\\<2.","groupId":"OG000","value":"NA"},{"comment":"Not estimable for n\\<2.","groupId":"OG001","lowerLimit":"4.6","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"20.0","upperLimit":"37.9","value":"29.0"},{"groupId":"OG003","lowerLimit":"2.5","upperLimit":"8.8","value":"5.7"},{"groupId":"OG004","lowerLimit":"3.3","upperLimit":"13.7","value":"13.7"},{"groupId":"OG005","lowerLimit":"5.4","upperLimit":"18.4","value":"7.5"},{"comment":"Not estimable.","groupId":"OG006","lowerLimit":"3.7","upperLimit":"NA","value":"14.5"}]}],"title":"irRECIST"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"12"}],"units":"Participants"}],"description":"DOSD was analyzed by the Kaplan-Meier approach for each tumor type. Stable disease (SD) was defined as not qualifying for complete response (CR), partial response (PR), or progression. All target lesions must have been assessed. Stable could follow PR only in the rare case that the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \\< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"OG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"OG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"OG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"OG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG004","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"},{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG005","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG006","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (maximum of 1606 days)","title":"Duration of Stable Disease (DOSD) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2","type":"SECONDARY","unitOfMeasure":"Months"}